Intervention Review

You have free access to this content

Steroids for acute spinal cord injury

  1. Michael B Bracken*

Editorial Group: Cochrane Injuries Group

Published Online: 18 JAN 2012

Assessed as up-to-date: 2 AUG 2011

DOI: 10.1002/14651858.CD001046.pub2


How to Cite

Bracken MB. Steroids for acute spinal cord injury. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD001046. DOI: 10.1002/14651858.CD001046.pub2.

Author Information

  1. Yale University Medical School, Department of Epidemiology & Public Health, New Haven, CT, USA

*Michael B Bracken, Department of Epidemiology & Public Health, Yale University Medical School, Box 20834, 60 College Street, New Haven, CT, 06520-8034, USA. michael.bracken@yale.edu.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 18 JAN 2012

SEARCH

[Analysis 1.1]
Analysis 1.1. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 1 Motor function at six weeks, six months and one year: all patients.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 2 Motor function at six weeks, six months and one year: <8 hours to treatment.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 4 Pinprick sensation at six weeks, six months and one year: <8 hours to treatment.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 5 Touch sensation at six weeks, six months and one year: all patients.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 6 Touch sensation at six weeks, six months and one year: <8 hours to treatment.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 7 All-cause mortality, <210 days.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 8 Wound infection at six weeks.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 9 GI haemorrhage at six weeks.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Moderate vs low-dose MPSS, 10-day regimen, Outcome 10 Sepsis at six weeks.
[Analysis 2.1]
Analysis 2.1. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 1 Motor function at six weeks, six months and one year: all patients.
[Analysis 2.2]
Analysis 2.2. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 2 Motor function at six weeks, six months, and one year: <8 hours to treatment.
[Analysis 2.3]
Analysis 2.3. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients.
[Analysis 2.4]
Analysis 2.4. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 4 Pinprick sensation at six weeks, six months and one year: <8 hours to treatment.
[Analysis 2.5]
Analysis 2.5. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 5 Touch sensation at six weeks, six months and one year: All patients.
[Analysis 2.6]
Analysis 2.6. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 6 Touch sensation at six weeks, six months and one year: <8 hours to treatment.
[Analysis 2.7]
Analysis 2.7. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 7 All-cause mortality <180 days.
[Analysis 2.8]
Analysis 2.8. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 8 Wound infection at 6 weeks.
[Analysis 2.9]
Analysis 2.9. Comparison 2 High-dose MPSS vs none, 24-hour regimen, Outcome 9 GI haemorrhage at 6 weeks.
[Analysis 3.1]
Analysis 3.1. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 1 Motor function at six weeks, six months and one year: all patients.
[Analysis 3.2]
Analysis 3.2. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 2 Motor function at six weeks, six months and one year: 3-8 hours to treatment.
[Analysis 3.3]
Analysis 3.3. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 3 Pinprick sensation at six weeks, six months and one year: all patients.
[Analysis 3.4]
Analysis 3.4. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 4 Pinprick sensation at six weeks, six months and one year: 3-8 hours to treatment.
[Analysis 3.5]
Analysis 3.5. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 5 Touch sensation at six weeks, six months and one year: all patients.
[Analysis 3.6]
Analysis 3.6. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 6 Touch sensation at six weeks, six months and one year: 3-8 hours to treatment.
[Analysis 3.7]
Analysis 3.7. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 7 Severe pneumonia at 6 weeks.
[Analysis 3.8]
Analysis 3.8. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 8 Severe sepsis at 6 weeks.
[Analysis 3.9]
Analysis 3.9. Comparison 3 High-dose MPSS for 48 hours vs 24 hours, Outcome 9 Mortality at 1 year.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 1 One-year motor function improvement score.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 2 One-year pinprick sensation improvement score.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Methylprednisolone for 23 hours and nimodipine for 7 days, Outcome 3 One-year touch sensation improvement score.